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Dissociation of Changes in Cardiovascular Mass and Performance
With Angiotensin-Converting Enzyme Inhibitors in Wistar-Kyoto and
Spontaneously Hypertensive Rats
EDWARD D. FROHLICH, MD, FACC, OSAMU SASAKI, MD
New Orleans, Louisiana
The effects of angioteasin-wavering enzyme inhibitors on
cardiovascular mass and function were measured in three
groups of 22 week old mate WistarvRyoto nornrotensive and
spontaneously hypertensive rats treated with CGS-16617,
eilazaprll or quinapri
. Left ventricular performance uses
assessed by electromagnetic flow meter during rapid whole
blood infusion before and after arterial pressure coed In-
creased abruptly with aortic sum; aortic dlstensibthy also
was assessed in vitro.
The systemic bemodynamic effects of these three agents
were simh'ar, yet their structural effects varied
. Although
left ventr.cular and aortic musizes diminished and right
vcatricuiar maw remained unchanged (with
all three
agents) in the spontaneously hypertensive rats, CGS-11617
and cflaauprfl alto reduced left ventricular man In the
Left ventricular hypertrophy develops over the natural his-
tory of hypertensive disease in humans with essential hyper-
tension and in rats with spontaneous hypertension as a
structural adaptation to the progressively increasing after-
load, although it continues to progress even when arterial
pressure stabilizes (1-4).
It therefore serves an adaptive
function in preventing the earlier emergence of left ventric-
ular failure (1-4); however, this effect may be offset, at least
in part, by the resultant independent risk of premature
cardiovascular morbidity and mortality (5,6)
.
If used long enough, antihypertensive therapy will dimin-
ish left ventricular mass (7), although under special labora-
tory conditions certain pharmacologic agents will rapidly
normalize left ventricular mass within 3 weeks in spontane-
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normotemive Wistar-Kyoto rats without changing aortic
mass. Ali three agents improved aortic distensibility
whether or not moss was decreased. Left venbicular strue.
tural changes were associated with variable changes to
pumping ability.
These dot, show, dthat reduced mesa ~
elated with angloteosin-converting enzyme lahibltor treat-
ment was not consistent in ventricles and aorta, that a
dissociation exists between structural and functional
changes and that reduction of cardiac man alone does not
relate to changes in chamber mss or to function. Thos,
biologic and pharm codynamk differences exlat among
aogioteosin-convertibg enzyme inhibitors as well as be-
tween clam of antihypertensive agents .
(J Am Cog Cardiol 1990;16 :1492-9)
ously hypertensive rats (8,9) and within 4 to 12 weeks in
patients with essential hypertension (3,4,10-12) . Determina-
tion of whether this pharmacologically induced decreased
left ventricular mass corrects for the inherent risk of hyper-
trophy requires prospective studies in which pressure is
allowed to return to pretreatment levels so that the benefit
from reduced left ventricular
mass itself can be dissociated
from the effect of the antihypertensive therapy . This is a
difficult proposition in light of the clinical ethical issues
involved (4).
In two earlier studies from our laboratory (13,14), the
pumping ability of the left ventricle that had undergone
reduction in mass with methyldopa or with captopril was
assessed at both pharmacologically reduced as well as pre-
treatment pressures. Improvement of left ventricular pump-
ing ability was not shown either at the pharmacologically
induced normalized arterial pressures or at its pretreatment
hypertensive pressure levels . The present study assesses
three additional angiotensin-converting enzyme inhibitors
that use the identical experimental protocol reported earlier
(13,14) and demonstrates qualitatively and quantitatively
different responses among classes of antihypertensive agents
0735.1097) ws3.50
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as well as within the angiotensin-converting enzyme inhibi-
tor group.
Methods
Experimental rats . Sixty spontaneously hypertensive
rats and 60 Wistar-Kyoto normotensive control male rats
(Charles River Co.) were divided into three equal subgroups
of 20 rats each for the two strains. Before treatment we
confirmed the existence of hypertension or normotension in
all spontaneously hypertensive rats and Wistar-Kyoto rats,
respectively, by tail-cuff plethysmography (15) . All rats were
maintained thereafter three to a cage and were fed standard
rat chow and tap water as desired and they were of the same
body weight. The protocol was approved previously by our
institutional animal care committee.
Drug dosing. The effects of the three angiotensin-
converting enzyme inhibitors (that is, CGS-16617, cilazapril
and quinapril) were determined on cardiac mass and left
ventricular pumping performance, as well as on aortic mass
and distensibility (the latter in vitro) . With each drug evalu-
ation 20 Wistar-Kyoto and 20 spontaneously hypertensive
rats were divided into two subgroups ; 10 rats received the
respective vehicle (thereby serving as a control) for each
drug and 10 the angiotensin-converting enzyme inhibitor .
Treatment was begun at age 19 weeks of age and was
administered once daily by gastric Savage for 3 weeks with the
following dosages: CGS-16617, 10 mg; cilazapril, 10 mg/kg
and quinapril 3 mg/kg body weight per day . After 3 weeks of
daily treatment each rat was studied hemodynamically.
Systemic hemodynamics . Two days before the conclusion
of the 3 week treatment period, a polyethylene tubing
(PE-50) was inserted into the left iliac artery under light ether
anesthesia and exteriorized through a subcutaneous tunnel
to the nape of the neck for direct measurement of arterial
pressure in the conscious state . At the conclusion of the
treatment period, mean arterial pressure and heart rate were
recorded on a Beckman recorder (model R612) connected to
a Statham (P23Db) transducer. When all rats were fully
recovered and conscious, arterial pressure and heart rate
were recorded 6 h after final administration of the angioten-
sin-converting enzyme inhibitor or vehicle
. Subsequently,
under light ether anesthesia another polyethylene catheter
(PE-90) was inserted into the right jugular vein so that whole
blood could be infused rapidly to determine left ventricular
pumping ability (13,14,16-I8). Another polyethylene cathe-
ter (PE-50) was placed into the right carotid artery to record
mean arterial pressure and pulse pressure directly by a
Statham (P23Db) transducer. This permitted continuous
recording of arterial pressure even during aortic constriction
(see following sections) (13,14) .
Tracheal intubation was accomplished with PE-240 tub-
ing to permit artificial ventilation with a small animal respi-
rator (Harvard model 680)
. The chest was then entered by
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electric cautery through a medial sternal incision and posi-
live end-expiratory pressure was maintained by submerging
the respirator outflow catheter tip under 1.0 to 1.5 cm of
water to prevent pulmonary atelectasis . Another polyethyl-
ene catheter (PE-50) was inserted into the left ventricle
through the left atrium to permit continuous measurement of
left ventricular end-diastolic pressure . Ascending aortic
blood flow was measured as cardiac output with a precali-
brated Statham electromagnetic flow probe (diameter 2 .5 mm)
whose electric signal was fed into the Beckman recorder (type
9053A( by a Statham electromagnetic flowmete : (SP 2202). The
zero line of aortic blood flow was adjusted to the flat portion of
the flow wave during the diastolic phase of flow. This zero line
was confirmed at the conclusion of each study with use of a
blood-filled aortic arch preparation . In this manner and under
continuous ether anesthesia, baseline systemic hemodynamic
values were recorded for at least 10 min after the conclusion of
all surgical procedures and then only when the rat was recog-
nized to be physiologically stable . Heart rate was determined
from a beat to beat analysis of the aortic flow curve using a
Beckman cardiotachometer (type 9857B) . Cardiac index was
calculated by dividing cardiac output by body weight, stroke
index by dividing cardiac index by heart rate and total periph-
eral resistance index by dividing mean arterial pressure by
cardiac index .
Left ventricular pumping ability. Whole blood obtained
from donor rats of the same strain and maintained at 37°C
was infused rapidly into the jugular vein (as an acutely raised
preload) over a I min period with a Harvard infusion pump
(model 945) . This infusion volume had been quantified
previously to be 40 ml/min per kg body weight . In this
fashion cardiac index, stroke index, left ventricular end-
diastolic pressure, heart rate, mean arterial pressure and
pulse pi~ssure could be determined at any time during the
rapid volume loading
. Left ventricular performance curves
were subsequently constricted by plotting stroke index
against left ventricular end-diastolic pressure during the
rapid I min volume loading (13,14,17,18) .
After all rapid whole blood volume infusion measure-
ments for left ventricular pumping ability were obtained, the
precise volume of blood that had been infused was with-
drawn. Then all hemodynamic indexes were permitted to
return to their original preinfusion levels in all rats treated
with an angiotensin-convening enzyme inhibitor and control
rats . When physiologic stability was achieved, a snare that
had been previously placed around the descending thoracic
aorta was occluded abruptly to elevate mean arterial pres-
sure to aretreatment (but with anesthesia) pressure levels
.
This intervention permitted comparison of left ventricular
(pumping) performance of the treated rats at the same mean
arterial pressure as in the untreated rats
.
In vitro aortic distensibilty
. At the conclusion of the
hemodynamic studies, each rat was killed by exsanguination
and the heart was removed carefully. The aorta then was
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Table 1. Comparison of Systemic Hemodynarnics of Untreated and Angiotensin-Converting Enzyme-Treated Normotensive Wistar-
Kyolo (WKY) and Spontaneously Hypertensive (SHR) Rats
ligated at two places, at the base of the ascending aorta and
at that portion of the aorta where its first intercostal arterial
branch began . The left carotid and left subclavian arteries
were also ligated . The PE-50 tubing that previously had been
inserted into the right carotid artery was connected to a
Statham P23Db pressure transducer to record intraaortic
arch pressure. Thus, this closed aortic arch preparation
permitted plotting of aortic pressure-volume curves . To
construct this curve, whole blood was infused at the rate of
3 .4 µUs during which time the intraaortic pressure varied
from 0 to 250 mm Hg. The volume changes were expressed
as a percent increase from the original volume that was
determined at the 0 mm Hg point of intraaortic pressure . In
this manner, in vitro aortic distensibility could be assessed
and compared with in vivo aortic distensibility .
Cardiac and aortic arch weights . Both atria were excised
carefully from the removed heart and the free wall of the
right ventricle was separated from the left ventricular cham-
ber; this was considered as right ventricular mass . The
intraventricular septum remained with the left ventricle. The
aortic arch was also removed carefully after determining the
in vitro aortic distensibility. Wet weights of the blotted
ventricles and aortic arch were determined carefully on a
grammatic balance both as absolute weight and as the ratio
of the respective
ventricular and aortic weights to total body
weight (and expressed
as mg/g or mg/kg) .
Statistical methods
. All calculated data are expressed as
the mean (± I SEM) . A two-way analysis of variance with
repeated measures was applied to analyze both the left
JACC Val. 16 . No .6
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'p < 0 .05 ve . . . espective casual rats; tp < 0.05 versus control WKY rats. Each group consists of 10 rats. Data are presented as mean values x SEM .
ventricular performance and aortic distensibility curves
(19,20). Baseline hemodynamic data and cardiac and aortic
weights were analyzed statistically using a one-way analysis
of variance and they subsequently subjected to Newman-
Keuls testing for multiple comparison (21). Statistical signif-
icance was established at the 95% confidence level.
Results
Systemic hemodynaodcs. Mean arterial pressure was sig-
nificantly greater in each spontaneous hypertensive rat
group than in its respective Wistar-Kyoto group before
administration of the three angiotensin-converting enzyme
inhibitors and it was reduced significantly in both strains
with angiotensin-converting inhibitor treatment (Table 1) .
Thus, with CGS-16617, cilazapril and quinapril mean arterial
pressure was reduced by 17%, 23% and 19%, respectively, in
the Wistar-Kyoto and by 21%, 24% and 17%, respectively,
in the spontaneously hypertensive rats . This mean arterial
pressure decrease was associated with a 21% and 2B%
reduction in reduced total peripheral resistance index in the
spontaneously hypertensive rats with the use of CGS-16617
and cilazapr0 but with only a 13% reduction with the use of
quinapril. Changes in total peripheral resistance index in the
Wistar-Kyoto rats were more variable, not decreasing with
CGS-16617 but falling more variably with cilazapril and
quinapril (by 21% and 10%, respectively) . The mean arterial
pressure and total peripheral resistance index changes after
administration of these angiotensin-converting enzyme in-
WKY
SHR
Hemodynamic Index Agents Control Treated Control Treated
Mean arterial CGS-16617 92 x 2 76 ± 1' 144 x 3t 113 ± 2'
pressure (mm Hg) Cdarapril 99 x 1 76 ± 4' 146 t 2t 110 ± 2'
Quinapril 96 *- 2 78 x 2' 141 x 1t 116 ± 2'
Heart rote (beaWmin) CGS-16617
283 0 4 280±7 284±8 263±5
Cilarapril 295 ± B 278±8 321±4 312±5
Quinapril 292 ± 5 285 ± 10 343 ± 5 329 ± 5
Tell ventricular end- CGS-16617
5
.8 0x
0.2 4.8'_0.1' 5 .0`_0
.21 4.6-0 .1
diastolic pressure (mm Hg) Cilampdl 5 .6 ± 0.1 4.5'_0.1 • 6.0x0.2 5.2**-0
.1-
Quinapril 5 .2 x 0.1 4.9 ±0.2 5.2±0.1 5.0±0 .1
Cardiac index (mUmin per kg) CGS-16617
296 x 6 249 ± 8'
221 x 3t
227 ± 10
Cilarapril 230 ± 6 225 ± t0 211 ± 5 223 x 6
Quinapril 242 x 6 226 ± 7 242 6 231 x 4
Snake index (mkbeat per kg) CGS-16617 1 .05 0 0.02 0.89 ± 0 .02' 0.78 ± 0.011 0 .87 x 0.05
Ciiampril 0 .78 x 0.02 0.81 x 0 .03 0.66 ± 0.021 0 .72 ! 0.02
Qeinapril 0 .83 x 0.02 0.78 0.71±0 .021 0 .70±0.01
Total Peripheral CGS-16617 0 .31 x 0.01 0.31 *- 0 .01 0.65 ± 0 .02) 0 .51 ± 0.03-
resistance index (0-kg)
Cilampril
0.43 x 0.01
0.35 ± 0 .03' 0.70 x 0.OZt 0.50 x 0.01'
Quinapril
0.40 ± 0.01
0.36 *- 0.01 0.58 ± 0.02+
0.51 ± 0.01'
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Table 2 . Comparison of Cardiac and Aortic Weights Expressed in Terms of Body Weight of Untreated and .Angiotensin-Converting
Enzyme-Treated Normotensive Wistar-Ksnto (WKY) and Spontaneously Hypertensive (SHR) Rats
WKY
SHR
Organ Weights
(mglg)
Total ventricular
weightlbody weight
Left ventricular
weightlbody weight
Right ventricular
weighl/hady weight
Aortic arch weight)
50% weight
'p < 0
.05 versus respective control tats
; 'p 10.05 versus control WKY rats
. Care are presented as mean values - 1 SEM.
hibitors were not associated with compensatory increases in
heart rate or cardiac index in either rat strain ; however, after
administration of CGS-16617 cardiac index declined by 1fi/,
thereby explaining the lack of reduction in calculated total
peripheral resistance index with the decline in mean arterial
pressure. This reduction in cardiac index after CGS-16617
was associated with a 17% fall in left ventricular end
diastolic pressure ; however, cardiac index did not decline in
association with a similar reduction in left ventricular end-
diastolic pressure (of 19%) after treatment with cilazapril .
There was no change in left ventricular end-diastolic pres-
sure in either strain after administration of quinapril .
Cardiovascular mass. Both total and left ventricular mass
indexes and aortic arch weight were significantly greater in the
untreated spontaneously hypertensive rats with respect to the
Wistar-Kyoto rats (Table 2)
; right ventricular mass did not
differ between the rat strains at this age . Each of the angioten-
sin-converting enzyme inhibitors reduced left ventricular and
aortic mass in the spontaneously hypertensive rats but only
CGS-16617 and cilazapril reduced the mass of the nonhyper-
trophied left ventricle in the Wistar-Kyoto rats. Moreover,
only cilazapril reduced aortic arch mass in the Wistar-Kyoto
rats. Right ventricular mass remained unchanged with all three
angiotensin-converting enzyme inhibitors (Table 2) .
Left ventricular pumping ability . To express a function
curve for the 'left ventricle in response to increased filling,
stroke index was plotted against increasing left ventricular
end-diastolic pressure during the I min rapid infusion of
whole blood (Figs
. 1, A to C) (16-18) . With CGS-16617
treatment left ventricular pumping ability in the Wistar-
Kyoto rats was depressed downward (p < 0.05), but with
increased left ventricular afterload this curve shifted no
further (Fig. IA) . In contrast to these responses in the
Wistar-Kyoto rats, the function curves of the spontaneously
hypertensive rats remained unchanged with treatment, at-
though on abruptly increasing afterload the function curve
did shift downward (p < 0.05) (Fig. IA) .
There were no significant differences among the untreated,
treated and treated-afterloaded left ventricles of the Wistar-
Kyoto groups given quinapril (Fig . IBI . These findings were
quite °imilar to those curves obtained with the Wistar-Kyoto
groups given CGS-16617 . In contrast to these responses in the
Wistar-Kyoto rats, quinapril shifted the curves upward in the
spontaneously hypertensive rats, although the function curve
for the treated-afterloaded left ventricle fell between the un-
treated and treated function curves (Fig . IB) .
With cilazapril the left ventricular pumping ability of both
Wistar-Kyoto and spontaneously hypertensive rats improved,
the curves shifting upward and to the right, but when left
ventricular afterload was increased abruptly, the curves be-
came depressed, especially at the higher left ventricular end-
diastolic pressures . However, this shift was depressed below
those curves of the untreated or treated Wistar-Kyoto and
spontaneously hypertensive rats (Fig
. IC) .
Aortic distensibility. When evaluated by our in vitro
assessment (Fig. 2, A to C), aortic distensibility
as signif-
icantly reduced in the untreated spontaneously hypertensive
rats with respect to the Wistar-Kyoto rats (at least p < 0
.05) .
This impaired aortic distensibility (with respect to the
Wistar-Kyoto rats) persisted with treatment with all three
angiotensin-convening enzyme inhibitors in the spontane-
ously hypertensive rats, although each of the three agents
significantly improved their respective in vitro distensibility
curves (Fig . 2, A to C) .
Discussion
In this study the three angiotensin-converting enzyme
inhibitors had similar systemic hetrodynamic effects, but
they produced different cardiovascular structural and func-
Control Treated
Control Treated
CGS-16617 2.88 - 0 .02 270 - 0 .03' 3 .34 0.040 3 .06 ` 0.03'
Cilazapril 2.84 x 0 .03 ''- .58 OJ:T 3.39 0 0.04' 2 .92 x 0.03°
Quinapril 2.72
-
0 .02 170 0 0.04" 3.28 0.0!7 - 902'
CGS-16611 2 . Is c 00 1 201
.
o"C' 265 ± 0 04' 136 ^ 0
.02'
Cilazapol 2 .21 - 0.03 96 - 0.05'
2 .73 ^ 0 .05' 2.30 0.02'
Quinapril 2 .10 002 ''-.07 - 0 .03 2 .67 ' 0.021 2.48 0.01'
CGS- 16617 0 .70 *_ 0.01 0.64 - 3 .02 0 .'71) x 11.01 0 .70 0
0
.112
CilazaPril 0.63 n 0.01 0 .62 n 091 0.66 -0
.01
0 .63 o O01
Quinapril 0.61-' 0.01 11 .63 x 1101 0-61 _ 001 062 x 0 .02
CGS-16617
43.8 x LI 45 9 c 13
72.6 ' 1 4' 56.1 ` 16'
Cdazapnl 53.4 1 .7
49
.0 x 1 .5° 80.5 "- .l' 62 .6
0
1 .5'
Quinapril 55 .5
: 1 .2
56 .1 0 1 .! 77.8 0 1
.3'
69.3 0 2.3'
1496
	
FROHLICH ET AL.
ACE INHIBITION AND CARDIAC PERFORMANCE
12
E
1 0
c 0.6
-60.6
N
04-
0 5.0 7.5 10.0 12.5 15.0 17.5
M
LVEDP (mmHg)
p.00s
o--o o.o.o M.JJ _
FU
0000sm _
'
F-y n.aq 9a
•
O,Tf
/ amen o.ool
•
0 5.0 7.5 10.0 12.5 15.0 17.5 20.0
LVEOP
(mmHg)
tional responses to the volume and pressure-volume inter-
ventions . All three agents reduced arterial pressure through
arteriolar dilation that decreased total peripheral resistance.
These changes were achieved without a compensatory in-
crease in heart rate or in cardiac index, and left ventricular
end-diastolic pressure did not increase with treatment .
These hemodynamic responses were similar to those re-
ported earlier in patients and experimental animals with
hypertension (10-12,22,23). Associated with these very sim-
ilar hemodynamic effects was a diminished left ventricular
and aortic mass in all spontaneously hypertensive rat
groups, although there were variable effects in the nortnoten-
sive Wistar-Kyoto rats without ventricular hypertrophy or
increased vascular wall mass . Right ventricular mass did not
change in either the hypertensive or the normotensive rats .
Structural-functional dissociation . The structural changes
produced by angiotensin-converting enzyme inhibitors were
associated with some changes in the pumping ability of the
left ventricle but these do nut necessarily relate to the
changes in cardiovascular mass produced by theantihyper-
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Figure 1
. Performance curves showing the pumping ability of
the left ventricle (stroke index versus left ventricular end-
diastolic pressure ILVEDPJ) in response to a rapid, I Into
infusion of whole blood to Wistar-Kyoto (WKY) (0) and
spontaneously hypertensive (SHR) (U) rats treated with
CGS-
16617
(A),
citazapril (B) or quinapril (CI . Symbols connected by
solid lines represent untreated rats ; those connected by later.
opted lines, rats treated with the angiotensin-converting en-
zyme inhibitor; and those connected by dotted lines, rats
treated with the angiotensin-converting enzyme inhibitor after
abrupt pressure increase . There are 10 rats in each group;
statistical significance is denoted by group connections .
tensive agents. Thus, a structural and functional dissociation
was again demonstrated to be associated with reversal of
cardiovascular mass with antihypertensive agents (I-
4,8,9,13,14,24-30) . In this study CGS-16617 reduced the
mass of the nonhypertrophied left ventricle in the Wistar-
Kyoto rats and this effect was associated with decreased
pumping ability . However, this functional response was not
aggravated when an increased afterload was superimposed
on the volume loading conditions. In the spontaneously
hypertensive rats with left ventricular hypertrophy, mass
was reduced by approximately the same amount but the
performance curve was not further diminished until the
increased afterload was superimposed.
In contrast to these responses with CGS-16617, in both
normotensive and hypertensive rats cilazapril improved the
pumping ability of both the Wismr-Kyoto and spontaneously
hypertensive rat left ventricles that had undergone similar,
and perhaps greater, reduction in mass . Moreover, when the
increased afterload was imposed on these left ventricles that
had undergone diminution in mass from their once hypertro-
JACC Vol . 16. No. 6
November 15. 1990 :1492-9
JACC Vol . 16. No . 6
November 15 .1990; 14
<
.2-9
A
	
Intra-aertte pressure (mmHg)
Figure 2 . In vitro aortic distensibility curves of ligated aortic
segments in which measured increments of whole blood are
added as pressure is measured in Wistar-Kyoto
(W KY) (0) and
spontaneously hypertensive (SHR) (®) rats treated with COS .
16617 (A), eilazapril (B) or quinapril (C). Symbols connected by
solid fines represent untreated rats and those connected by
interrupted lines. treated rats. There are 10 rats in each group ;
statistical significance is indicated .
phied or nonhypertrophied state, pumping ability became
diminished . However, this reduced performance was not
significantly different from that shown from those function
curves of treated or untreated spontaneously hypertensive
rats. Finally, with quinapril, which did not decrease left
ventricular mass in the Wistar-Kyoto rats and had the least
effect in diminishing left ventricular mass in the spontane-
ously hypertensive rats, there was no alteration of left
ventricular pumping ability in the Wistar-Kyoto rats, and the
function curve improved in the spontaneously hypertensive
rats .
Comparison with previous studies . These findings are in
striking contrast with those from our studies of methyldopa
(13) and captopril (14) in which we followed the identical
protocol in male Wistar-Kyoto and spontaneously hyperten-
sive rats of the same age . In those studies methyldopa and
captopril produced systemic hemodynamic effects qualita-
tively and quantitatively similar to the effects obtained with
the three an;iotensin-converting enzyme inhibitors in this
study. However, in contrast to the structural effects pro-
duced by these three agents, methyldopa reduced right
-
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ventricular mas in both the Wistar-Kyoto and spontane-
ously hypertensive rats but did not affect ascending aortic-
arch mass (13) .
Moreover, CGS-16617 and cilazapril, like
methyldopa, diminished left ventricular mass in the Wistar-
Kyoto rats, although quinapril did not . In contrast to the
three agents in the present study, captopril reduced left
ventricula mass in both the Wistar-Kyoto and spontane-
ously hypertensive rats but reduced right ventricular mass
only in the spontaneously hypertensive rats (14).
These findings underscore our earlier observations of a
dissociation between the systemic hemodynamic and struc-
tural responses that takes place with the development (or
reversal) of left ventricular hypertrophy in humans with
essential hypertension as well as in animals with experimen-
tal forms of hypertension (1-4,28,29) . The present findings
extend the thesis by demonstrating that this dissociation also
occurs with respect to the hemodynamic and structural
responses of nonhypertrophied ventricles and aorta in nor-
motensive rats with diminished ventricular mass associated
with administration of pharmacologic agents
. This concept is
supported further by our recent observation of increased
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right ventricular mass in Wislar-Kyoto rats and some spon-
taneously hypertensive rats associated with treatment with
one of several calcium antagonists (30).
Mechanisms. At present it is not possible to define the
mechanism or mechanisms responsible for the reduced car-
diovascular mass or for the variable functional responses to
these structural changes . Hemodynamic events are of major
importance in producing left ventricular hypertrophy (1,2)
and nonhemodynamic mechanisms must also participate to a
greater or lesser extent in the situations that occur experi-
mentally or clinically (1-4,28,31,32) . Reduced left ventricu-
lar and aortic mass result from pharmacotherapy with a
variety of antihypertensive agents (such as beta-adrenergic
receptor blockers, angiotensin-converting enzyme inhibitors
or calcium antagonists) (1-4), and mass does not decrease
with other effective hypotensive agents (such as direct-
acting smooth muscle vasodilators and alpha-adrenergic
receptor blockers) (9,25,27) favoring participation of nonhe-
modynamic factors (28,29).
Among those factors that have been incriminated are
intramyocytic protooncogenes (4,33), events involving the
intramyocytic renin-angiotensin system
(4,31,32,34,35), and
changes in the intracellular calcium ionic milieu (4,36,37) .
Confounding the complexity of these possibilities are the
obvious pharmzcologic considerations
of cellular penetrauee
by
the various antihypertensive drugs due to their pharma-
codynamic and pharmacokinetic properties and the respon-
siveness of the aforementioned intracellular systems to these
agents .
Therapeutic implications
. The importance of the present
study concerns the differences in the effects
of the various
antihypertensive agents on cardiovascular structure not only
from one antihypertensive drug class to another, but also
within the same class of pharnracolsgic agents (such as the
ang_iotensin-converting enzyme inhibitors reported herein)
.
It is necessary to mention the clinical implications of the
role of
antihypertensive agents in diminishing the mass of the
hypertrophied ventricles . Retrospective and prospective
studies have shown that left ventricular hypertrophy in itself
confers an independent risk of increased cardiovascular
morbidity and mortality (5,6,38) . It is not known what
mechanisms account for this increased risk nor whether
pharmacologically induced reversal of the hypertrophic pro-
cess can reduce it. Until prospective studies
demonstrate
that risk has been reduced (after hypertrophy is reversed
when the antihypertensive and antiarrhythmic effects of the
drugs have dissipated), it seems wise to withhold further
clinical, scientific and commercial speculation.
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